SAN DIEGO, April 18 /PRNewswire-FirstCall/ -- Nanogen, Inc.
(Nasdaq: NGEN), developer of advanced diagnostic products, announced today
that it has entered into a supply and license agreement with deCode Genetics
to provide a new genomics assay for single nucleotide polymorphism (SNP)
discovery, validation and screening. The assay incorporates a full range of
Nanogen's products, including the Eclipse(R) Dark Quencher, new DNA linker
technology, modified bases and novel fluorescent dyes, and allows rapid SNP
analysis on a large number of patient samples.
"The products and assay that we will provide deCode represent our
comprehensive product menu available from the recent merger of Nanogen and
Epoch Biosciences," said Howard C. Birndorf, Nanogen's chairman of the board
and CEO. "We are pleased deCode has joined our roster of licensing partners
eager to tap our growing portfolio of products that enable rapid,
high-throughput genetic analysis."
About Nanogen, Inc.
Nanogen's advanced diagnostics provide physicians and patients worldwide
with sophisticated information to predict, diagnose and treat disease.
Research and clinical reference labs use the highly accurate and reliable
NanoChip(R) Molecular Biology Workstation, NanoChip(R) Electronic Microarray
and broad suite of analyte specific reagents to develop diagnostic tests for
variety of diseases. Nanogen also offers a broad portfolio of patented
nucleic acids chemistries and molecular tools that accelerate genomic analysis
and are compatible with many systems. The SynX subsidiary offers a line of
point-of-care diagnostic tests and is building expertise in cardiac related
health conditions. Nanogen's ten years of pioneering research involving
nanotechnology may also have future applications in medical diagnostics,
biowarfare and other industries. For additional information please visit
Nanogen's website at www.nanogen.com.
This press release contains forward-looking statements that are subject to
risks and uncertainties that could cause actual results to differ materially
from those set forth in the forward-looking statements, including whether
patents owned or licensed by Nanogen will be developed into products, whether
the patents owned by Nanogen offer any protection against competitors with
competing technologies, whether products under development can be successfully
developed and commercialized, whether results reported by our customers or
partners can be identically replicated, and other risks and uncertainties
discussed under the caption "Factors That May Affect Results" and elsewhere in
Nanogen's Form 10-K or Form 10-Q most recently filed with the Securities and
Exchange Commission. These forward-looking statements speak only as of the
date hereof. Nanogen disclaims any intent or obligation to update these
SOURCE Nanogen, Inc.